MX375355B - Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. - Google Patents

Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Info

Publication number
MX375355B
MX375355B MX2016009665A MX2016009665A MX375355B MX 375355 B MX375355 B MX 375355B MX 2016009665 A MX2016009665 A MX 2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A MX 375355 B MX375355 B MX 375355B
Authority
MX
Mexico
Prior art keywords
methods
compositions
intracerebral hemorrhage
treating
treating intracerebral
Prior art date
Application number
MX2016009665A
Other languages
English (en)
Other versions
MX2016009665A (es
Inventor
Joachim Fruebis
Marcus E Carr
Debra D Pittman
Reema Jasuja
Steven Arkin
Sunita Hett
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016009665A publication Critical patent/MX2016009665A/es
Publication of MX375355B publication Critical patent/MX375355B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La divulgación proporciona composiciones y métodos para el tratamiento o la prevención de la hemorragia cerebral (ICH) en un sujeto mediante la administración de una variante de FXa.
MX2016009665A 2014-01-24 2015-01-15 Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. MX375355B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
MX2016009665A MX2016009665A (es) 2016-11-14
MX375355B true MX375355B (es) 2025-03-04

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009665A MX375355B (es) 2014-01-24 2015-01-15 Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Country Status (18)

Country Link
US (2) US20160375109A1 (es)
EP (1) EP3096779B1 (es)
JP (1) JP6624787B2 (es)
KR (3) KR20160093731A (es)
CN (2) CN105934250A (es)
AU (1) AU2015208819B2 (es)
BR (1) BR112016014617A2 (es)
CA (1) CA2937418A1 (es)
DK (1) DK3096779T3 (es)
ES (1) ES2772802T3 (es)
HU (1) HUE047588T4 (es)
IL (1) IL246637A0 (es)
MX (1) MX375355B (es)
PL (1) PL3096779T3 (es)
PT (1) PT3096779T (es)
RU (1) RU2016126423A (es)
SI (1) SI3096779T1 (es)
WO (1) WO2015110939A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014210830A1 (en) 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006144397A (ru) * 2004-06-21 2008-07-27 Ново Нордиск Хелс Кеа Аг (Ch) ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US8354377B2 (en) * 2008-01-18 2013-01-15 Novo Nordisk Health Care Ag Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
CN102625712B (zh) * 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
CN104755492A (zh) * 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
AU2014210830A1 (en) * 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition

Also Published As

Publication number Publication date
PT3096779T (pt) 2020-02-21
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
DK3096779T3 (da) 2020-02-24
MX2016009665A (es) 2016-11-14
RU2016126423A3 (es) 2018-03-01
EP3096779B1 (en) 2019-12-18
EP3096779A1 (en) 2016-11-30
ES2772802T3 (es) 2020-07-08
KR20180014221A (ko) 2018-02-07
CA2937418A1 (en) 2015-07-30
BR112016014617A2 (pt) 2017-09-19
SI3096779T1 (sl) 2020-03-31
JP6624787B2 (ja) 2019-12-25
CN105934250A (zh) 2016-09-07
AU2015208819A1 (en) 2016-06-30
JP2015147764A (ja) 2015-08-20
WO2015110939A1 (en) 2015-07-30
IL246637A0 (en) 2016-08-31
KR20160093731A (ko) 2016-08-08
HUE047588T2 (hu) 2020-04-28
HUE047588T4 (hu) 2020-06-29
RU2016126423A (ru) 2018-03-01
CN112156176A (zh) 2021-01-01
AU2015208819B2 (en) 2020-01-23
US20190231856A1 (en) 2019-08-01
US20160375109A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
IL251759A0 (en) Preparations and methods for treating insomnia
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
PH12017501864A1 (en) Compositions and methods for treating autism
GB2542080B (en) Non-reducing stabilization complexant for acidizing compositions and associated methods
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12016501838A1 (en) Compounds and their methods of use
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MY167350A (en) Fat-and-oil composition and chocolate
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX375355B (es) Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.
IL249152A0 (en) Botulinum toxin for use in the treatment of paratonia
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201407949D0 (en) Compositions and methods for treating biofilms

Legal Events

Date Code Title Description
FG Grant or registration